Search Results - "Barkman, Hannerieke J"

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients by Lin, Lishi, Barkman, Hannerieke J., Smit, Egbert F., de Langen, Adrianus J., Steeghs, Neeltje, Beijnen, Jos H., Huitema, Alwin D. R.

“…the study aims to evaluate whether high plasma trough levels of the kinase inhibitors (K.I.s) crizotinib, alectinib, osimertinib, dabrafenib, and trametinib…”
Get full text

A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute by Heinhuis, Kimberley M., Barkman, Hannerieke J., Beijnen, Jos H., Hendrikx, Jeroen J. M. A.

“…Background There is a strong rationale for fixed-dosing of monoclonal antibodies in oncology. Although fixed-dosing of recently introduced monoclonal…”
Get full text

Redispensing of expensive oral anticancer medicines: A practical application by Akgöl, Kübra, van Merendonk, Lisanne N, Barkman, Hannerieke J, van Balen, Dorieke EM, van den Hoek, Hester L, Klous, Marjolein G, Hendrikx, Jeroen JMA, Huitema, Alwin DR, Beijnen, Jos H, Nuijen, Bastiaan

“…Introduction Increasing use of expensive oral anticancer medicines comes with the downside of a financial and environmental burden, partially caused by unused…”
Get full text